Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29807934 | 1.00 | NPC1 (0.56) | NPC1MEN1HCRTR1KMT2APOLB | |
| SCHEMBL28687576 | 0.85 | ROCK2 (0.54) | KMT2ALMNAHDAC1MMP13MAPK1 | |
| SCHEMBL30592138 | 0.84 | MMP13 (0.60) | KMT2APOLBLMNAMAOBMMP13 | |
| SCHEMBL23521923 | 0.84 | MMP13 (0.60) | KMT2APOLBLMNAMAOBMMP13 | |
| SCHEMBL29808056 | 0.83 | CYP2C19 (0.58) | MEN1KMT2APOLBLMNAMAPK1 | |
| SCHEMBL23521747 | 0.83 | CYP2C19 (0.58) | MEN1KMT2APOLBLMNAMAPK1 | |
| SCHEMBL23521924 | 0.83 | KMT2A (0.55) | KMT2ALMNAHDAC2HDAC6MMP13 | |
| SCHEMBL29808051 | 0.83 | KMT2A (0.55) | KMT2ALMNAHDAC2HDAC6MMP13 | |
| SCHEMBL23521925 | 0.83 | TSHR (0.51) | MEN1KMT2ALMNAAPEX1HDAC1 | |
| SCHEMBL29807696 | 0.83 | TSHR (0.51) | MEN1KMT2ALMNAAPEX1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4104902-B1 | COMPOUNDS AND MEDICAMENTS USING SAME | IRIMAJIRI THERAPEUTICS INC (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-11780841-B2 | 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same | IRIMAJIRI THERAPEUTICS INC. (JP) | 2023-10-10 | — | — | US | disclosed |
| EP-3838901-B1 | COMPOUND FOR TREATMENT OF RABIES AND METHOD FOR TREATMENT OF RABIES | IRIMAJIRI THERAPEUTICS INC (JP) | 2023-09-27 | — | — | EP | disclosed |
| EP-4104902-A1 | COMPOUND AND DRUG CONTAINING SAME | Oita University Institute of Advanced Medicine, Inc. (JP) | 2022-12-21 | — | — | EP | disclosed |
| CN-115260193-A | Compounds and methods for treating rabies | 株式会社大分大学先端医学研究所 | 2022-11-01 | — | — | CN | disclosed |
| CN-115052661-A | Compound and drug using the same | 株式会社大分大学先端医学研究所 | 2022-09-13 | — | — | CN | disclosed |
| CN-112839944-B | Compounds and methods for treating rabies | 株式会社大分大学先端医学研究所 | 2022-08-05 | — | — | CN | disclosed |
| US-20220194942-A1 | 3,6-METHANO-1H-PYRROLO[3,2-b]PYRIDINE AND 3,6-METHANO-1H-PYRROLO[3,2-c]PYRIDINE COMPOUNDS AND MEDICAMENTS USING SAME | IRIMAJIRI THERAPEUTICS INC. (JP) | 2022-06-23 | — | — | US | disclosed |
| US-11292794-B2 | 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-C]pyridine compounds and medicaments using same | OITA UNIVERSITY INSTITUTE OF ADVANCED MEDICINE, INC. (JP) | 2022-04-05 | — | — | US | disclosed |
| EP-3838901-A1 | COMPOUND FOR TREATMENT OF RABIES AND METHOD FOR TREATMENT OF RABIES | Oita University Institute of Advanced Medicine, Inc. (JP) | 2021-06-23 | — | — | EP | disclosed |
| CN-112839944-A | Compounds and methods for treating rabies | 株式会社大分大学先端医学研究所 | 2021-05-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292794-B2 | 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-C]pyridine compounds and medicaments using same | AVPR1B, F12, SDHB | NPC1 3009/4885MEN1 203/4885HCRTR1 2413/4885 |
| US-11780841-B2 | 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same | AVPR1B, AVPR2, F12 | NPC1 3114/4885MEN1 248/4885HCRTR1 2763/4885 |
| US-20220194942-A1 | 3,6-METHANO-1H-PYRROLO[3,2-b]PYRIDINE AND 3,6-METHANO-1H-PYRROLO[3,2-c]PYRIDINE COMPOUNDS AND MEDICAMENTS USING SAME | AVPR1B, AVPR2, F12 | NPC1 3114/4885MEN1 248/4885HCRTR1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.